| Literature DB >> 28279459 |
Sarah M Bartsch1, Jennifer K Peterson2, Daniel L Hertenstein1, Laura Skrip3, Martial Ndeffo-Mbah3, Alison P Galvani3, Andrew P Dobson2, Bruce Y Lee4.
Abstract
BACKGROUND: Mathematical models can help aid public health responses to Chagas disease. Models are typically developed to fulfill a particular need, and comparing outputs from different models addressing the same question can help identify the strengths and weaknesses of the models in answering particular questions, such as those for achieving the 2020 goals for Chagas disease.Entities:
Keywords: Chagas disease; Model; Model comparison; Simulation; Trypanosoma cruzi
Mesh:
Year: 2017 PMID: 28279459 PMCID: PMC5549789 DOI: 10.1016/j.epidem.2017.02.004
Source DB: PubMed Journal: Epidemics ISSN: 1878-0067 Impact factor: 4.396
Model input parameters, values, and sources.
| Parameter | PHICOR/CIDMA Model | Princeton Model | Source | ||
|---|---|---|---|---|---|
|
|
| ||||
| Symbol | Value | Symbol | Value | ||
| Developing chronic Chagas | 25 | – | ( | ||
| disease given indeterminate phase | |||||
| Chagas related mortality during acute stage | 1 | – | (Bern et al., 2017) | ||
| Chagas related mortality during chronic stage (20 years and older, annually) | 7.84 | – | ( | ||
| Transmission to dogs given bite of infected vector (% per bite) | 0.000008–0.0012 | – | |||
| Transmission to humans given bite of infected vector (% per bite) | 0.000001–0.000011 | 0.00058 | ( | ||
| Transmission from acute stage to triatomine (% per bite) | 0.4928–0.7392 | 0.61 | ( | ||
| Transmission from indeterminate and chronic stage to triatomine (% per bite) | 0.016–0.432 | 0.026 | ( | ||
| Transmission from dog to triatomine (% per bite) | 0.19–0.56 | – | |||
| Triatomine feeding proportion for humans | 0–1 | – | ( | ||
| Triatomine contact rate (per bug per year) | 41 | 41 | ( | ||
| Triatomine birth rate (per bug per year) | 36 | 36 | ( | ||
| Triatomine death rate (per year) | 1.73 | 1.73 | ( | ||
| Human birth rate | 3.2× death rate ( | 2× death rate | |||
| Human death rate (peryear) | 0.0149 | 0.0149 | ( | ||
| Additional Chagas related mortality rate during chronic stage (30 years and older) | – | 0.00263386 | Assumption | ||
| Dog birth rate | Same as death rate | – | |||
| Dog death rate (per month) | 0.01667 | – | Assumption | ||
| Number of humans | 10,000 | 11,252 ( | |||
| Number of dogs (per person) | 0.393 | – | ( | ||
| Triatomine carrying capacity (per person) | 50 | – | ( | ||
| Duration between the acute phase and the indeterminate phase (weeks) | 6 | 6 | ( | ||
| Duration between the indeterminate phase and chronic phase (years) | 20 | – | ( | ||
| – | 1 | ( | |||
Value fitted during calibration process.
Fig. 1Model outline for a) the PHICOR/CIDMA model, and b) the Princeton model (i denotes different age groups in both models).
Fig. 2Entomological surveillance data for triatomine bugs and triatomine-infested houses from Ache 2001 for the time period of 1958–1998. The blue line indicates the percentage of houses infested with triatomine bugs; we assume the proportion of humans at risk of Chagas disease varies directly with this index. The green line is the average number of triatomine bugs per house, including those that are not infested. The red line is the average number of triatomine bugs per infested house, calculated from the two prior indices. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Average (range) simulated T. cruzi seroprevalence (%) for each time period using the PHICOR/CIDMA Model compared to historical Venezuelan data.
| Time Periods (Years) | ||||
|---|---|---|---|---|
|
| ||||
| 1958–1968 | 1969–1979 | 1980–1989 | 1990–1998 | |
| Ages 0–19 years | 26.3 (18.3–29.8) | 6.0 (3.4–11.0) | 1.7 (0.9–2.6) | 1.1 (0.42–2.0) |
| Ages 20–39 years | 55.3 (46.6–64.7) | 32.3 (26.9–36.5) | 18.3 (11.5–27.6) | 10.4 (5.5–16.8) |
| Ages 40 years and older | 65.5 (62.2–68.5) | 44.4 (38.2–52.7) | 44.3 (36.2–48.9) | 37.1 (27.2–43.9) |
| Calibrated | Calibrated | Calibrated | Generated | |
| Ages 0–19 years | 25.4 (15.9–39.5) | 10.8 (6.3–15.8) | 4.2 (2.6–6.3) | 1.7 (1.1–2.5) |
| Ages 20–39 years | 55.5 (42.3–68.8) | 32.2 (21.9–42.2) | 15.8 (10.8–21.8) | 7.8 (5.4–10.7) |
| Ages 40 years and older | 63.4 (68.0–58.3) | 51.9 (43.6–58.2) | 36.7 (30.1–43.5) | 25.0 (20.3–30.0) |
| Calibrated | Calibrated | Generated | Generated | |
| Ages 0–19 years | 24.8 (14.8–39.5) | 9.8 (5.5–14.7) | 3.6 (2.1–5.5) | 1.4 (0.9–2.1) |
| Ages 20–39 years | 54.9 (41.3–68.8) | 31.0 (20.6–41.1) | 14.6 (9.8–20.4) | 7.0 (4.8–9.8) |
| Ages 40 years and older | 63.0 (57.4–68.0) | 50.7 (42.2–57.3) | 35.3 (28.7–42.1) | 23.7 (19.2–28.6) |
NOTE: average across all the simulated years and runs during each time period; range represents the minimum and maximum over the time period across all simulation runs.
Average for age-groups combined from data reported in Ache and Matos (Ache and Matos, 2001); range represents the lower and upper bounds of the 95% confidence intervals reported for the individual age-groups.
Average (95% confidence interval) simulated T. cruzi seroprevalence (%) for each time period using the Princeton Model compared to historical Venezuelan data.
| Time Periods (Years) | ||
|---|---|---|
|
| ||
| 1980–1989 | 1990–1998 | |
| Ages 0–9 years | 1.1 (0.9–1.2) | 0.5 (0.42–0.56) |
| Ages 10–19 years | 2.4 (2.2–2.6) | 1.8 (1.6–2.0) |
| Ages 20–29 years | 12.4 (11.5–12.8) | 5.9 (5.5–6.3) |
| Ages 30–19 years | 26.6 (25.5–27.6) | 16.1 (15.4–16.8) |
| Ages 40–49 years | 37.5 (36.2–38.8) | 28.3 (27.2–29.4) |
| Ages 50 years and older | 48.0 (47.0–48.9) | 43.0 (42.1–43.9) |
| Ages 0–9 years | – | 0.73 (0.71–0.75) |
| Ages 10–19 years | – | 1.90 (1.88–1.93) |
| Ages 20–29 years | – | 7.18 (6.99–7.37) |
| Ages 30–19 years | – | 18.41 (18.02–18.81) |
| Ages 40–49 years | – | 30.39 (30.01–30.78) |
| Ages 50 years and older | – | 45.23 (45.07–45.39) |
| Ages 0–9 years | 2.93 (2.88–2.98) | 1.30 (1.27–1.33) |
| Ages 10–19 years | 6.84 (6.72–6.96) | 3.63 (3.58–3.69) |
| Ages 20–29 years | 16.81 (16.37–17.25) | 8.09 (7.98–8.20) |
| Ages 30–19 years | 27.76 (27.30–28.21) | 14.61 (14.39–14.82) |
| Ages 40–49 years | 41.98 (41.56–42.40) | 24.90 (24.53–25.27) |
| Ages 50 years and older | 43.01 (42.95–43.07) | 39.82 (39.64–40.01) |
Values are average (95% confidence interval) as reported in Ache and Matos (Ache and Matos, 2001).
Fig. 3Simulated seroprevalence from the PHICOR/CIDMA model a) T. cruzi seroprevalence in the total population over the four time periods, and b) age-stratified seroprevalence over time with the average simulated seroprevalence compared to the historical seroprevalence when targeting the last two time periods.
Fig. 4Simulated seroprevalence from the Princeton model for each age group a) T.cruzi seroprevalence in the total population over the four time periods, and b) age-stratified seroprevalence over time with the average simulated seroprevalence compared to the historical seroprevalence when targeting the last two time periods.
Fig. 5Comparison of models with historical data a) the average total population seroprevalence when targeting the last time period, b) the average total population seroprevalence when targeting the last two time periods, c) simulated T. cruzi seroprevalence among triatomines when targeting the last time period, and d) simulated T. cruzi seroprevalence among triatomines when targeting the last two time periods.